![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, October 30, 2021 10:57:50 AM
As Linda stated that to get TLD ready is the first, second and third priority of the company. Yes why bother being distracted from funding and seeking that manufacturing readiness before TLD announcement in whatever form either journal publication or not.
Yes everyone knows manufacturing readiness is IMPORTANT, but I have not seen any small biotech company seeking RA approval of its drug/biological product which has put manufacturing readiness first or at least as equal as getting TLD available for the public in importance like what Linda has been doing for DCVax-L approval.
So why has she been doing it in the opposite way?
The whole context of my previous post as below:
Regulatory inspection of the underlining drugs or biological products for their commercial readiness is usually the LAST STEP in regulatory approving process for the underlining products.
It usually goes like this: a biotech company develops a drug or biological product; have a review meeting with RAs for submitting NDA or BLA; NDA/BLA submission for application; application reviewed; labeling; manufacturing facility inspection; drug/biological product approval or issuance of a response letter.
So why the company has decided to move this last step backward, or the company has actually delayed all other steps to close to or coincide with this last step?
Why it took MHRA a whole few months to finally set its feet on the facility for inspection. A merely caseload as excuse seems convenient not concrete.
Discount Linda's evil motives to fund Advent to a commercial scale at the cost of nwbio shareholders while maintaining this prolonged quiet period, because the odds of DCVax-L gets approved is very high and she can also build Advent after D is approved.
So is this recently happened MHRA inspection of Sawston facility is equivalent to the LAST STEP of the DCVax-L approval process, besides the obvious Advent license application?
So is it reasonable to think when MHRA issues a license to Advent, it in effect approves the commercial use of DCVax-L in UK at least?
Then within the next couple of months, we will see license issuance, shortly followed by approval of DCVax-L.
When approved, NWBio will easily be worthy of $10-20 billions in short to medium term which is equivalent to a share price in the range of about $10-20 per share.
Yes selling at merely $1 and $1.10 per share instead of buying or holding, the Linda friendlies Island boys and vulture funds have no brains.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM